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Background: Secondary lymphoid tissue chemokine (SLC) is a key CC chemokine for chemotaxis of immune cells
and has been an attractive candidate for anti-tumor treatments. However, among the immune cells recruited by
SLC to tumors, the CD25+ Foxp3+ regulatory T cells (Tregs) compromise the anti-tumor effects. In this study, we
proposed the combination therapy of intratumoral co-administration of SLC and anti-CD25 monoclonal antibodies
(mAbs). We hypothesized that the intratumoral injections of SLC and depletion of Tregs would have stronger
inhibition effects on the progression of hepatocellular carcinoma (HCC) in mice.
Methods: C57BL/6 mice were inoculated subcutaneously with the murine HCC cell line, and mice with visible
tumors were treated intratumorally with SLC, SLC plus anti-CD25 mAbs or the control antibodies. The percentages
of Tregs, effector CD8+ T cells and CD4+ T cells were checked in the tumors, lymph nodes, spleen and liver at
regular intervals. The levels of intratumoral IL-12, IFN-γ, IL-10 and TGF-β1 were evaluated. The final anti-tumor
effects were measured by the tumor volume and weight as well as the intratumoral activity of MMP2 and MMP9.
Bone-marrow-derived dendritic cells were used to explore the mechanisms of maturation induced by SLC in vitro.
Results: Our experiments showed the combination therapy significantly decreased the frequency of Tregs, and
increased CD8+ T cells and CD4+ T cells at tumor sites. These alterations were accompanied by an increased level of
IL-12 and IFN-γ, and decreased level of IL-10 and TGF-β1. Unexpectedly, we observed a significantly decreased
percentage of Tregs, and increased CD8+ T cells and CD4+ T cells in the lymph nodes, spleen and liver after the
combination therapy. The growth and invasiveness of HCC was also maximally inhibited in the combination therapy
compared with the SLC alone. Furthermore, we confirmed SLC induced the maturation of DCs via NF-κB p65 and
this maturation would benefit the combination therapy.
Conclusions: Our data demonstrated that intratumoral co-administration of SLC and anti-CD25 mAbs was an
effective treatment for HCC, which was correlated with the altered tumor microenvironment and systemically
optimized percentages of Tregs, CD8+ T cells and CD4+ T cells in peripheral immune organs.
Keywords: SLC, DCs, Tregs, HCC, Anti-tumor immunity* Correspondence: cmliang@fudan.edu.cn
†Equal contributors
1Principle Investigator of the Lab of Tumor Immunology, the Department of
Anatomy and Histology & Embryology, Shanghai Medical College, Fudan
University, 138 Yixueyuan Road, Shanghai 200032, P R China
2Key laboratory of Carcinogenesis and Cancer Invasion, Liver Cancer Institute,
Zhongshan Hospital, Shanghai Medical College, Ministry of Education, Fudan
University, Shanghai, P R China
© 2013 Chen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Chen et al. Molecular Cancer 2013, 12:153 Page 2 of 11
http://www.molecular-cancer.com/content/12/1/153Background
Secondary lymphoid tissue chemokine (SLC, also known
as CCL21) is an important CC chemokine which can re-
cruit various immune cells such as dendritic cells (DCs)
and T cells [1]. In addition, recent research from our
group and others has demonstrated SLC can induce the
maturation of DCs [2,3]. These properties make SLC an
attractive candidate for anti-tumor treatments [4]. In-
deed, several studies have demonstrated intratumoral
administration of SLC elicits significant tumor regres-
sion [5,6]. We have also shown that intratumorally up-
regulating the level of SLC in hepatocellular carcinoma
(HCC) is an effective strategy to halt the progression of
tumors [3,7].
Among the immune cells at tumor sites, there exists a
group of regulatory T cells (Tregs) that are key compo-
nents in tumor immune suppression. They are broadly
identified as CD4+ T cells that highly express CD25 and
Foxp3 [8]. Tregs act by suppressing the activation, pro-
liferation and function of other immune cells [9]. In-
creasing evidence indicates that Tregs accumulate in the
tumor microenvironment (TME) and consequently in-
hibit the anti-tumor immunity [10-12]. This could ex-
plain the efficacy of anti-CD25 monoclonal antibodies
(mAbs) treatment in inducing tumor rejection in animal
models [13-15].
In light of these results, we proposed the combination
therapy of intratumoral co-administration of SLC and
anti-CD25 mAbs. In this study, we found the combin-
ation therapy decreased the frequency of Tregs, and in-
creased CD8+ T cells and CD4+ T cells at tumor sites,
with increased levels of IL-12 and IFN-γ and decreased
IL-10 and TGF-β1. Importantly, we observed the systemic
optimization of Tregs, CD8+ T cells and CD4+ T cells in
the lymph nodes, spleen and liver after the combination
therapy. The growth and invasiveness of HCC was
maximally inhibited in the combination therapy. In
vitro experiments confirmed that SLC-induced matur-
ation of DCs was mediated by the NF-κB p65, which
benefited the SLC-based combination therapy. These
data provided interesting clues for clinical immunother-
apy in HCC.
Results
Depletion of Tregs by anti-CD25 mAbs in the murine
HCC model
First we verified the efficacy of depletion of Tregs after
anti-CD25 mAbs injection in tumors. Representative
data of CD25+ Foxp3+ Tregs was shown by FACs and
IHC (Figure 1A and B). The results from all treated and
control mice were summarized and provided in a curve
diagram. As shown in Figure 1C, from day 1 to 9 post-
treatment, intratumoral Tregs remained essentially con-
stant at the significantly lowest level in SLC-anti-CD25mAbs treated mice, whereas Tregs in the control mice
were the highest and showed a linear increase. The SLC
group showed a modest increase of Tregs with a similar
pattern as the control group. Interestingly, there was a
sharp increase of Tregs in all three groups from day 7 to
day 9 (Figure 1C and D).
Dynamic changes of CCR7 and Foxp3 in tumors under the
combination therapy
CCR7 was detected in the thymus, lymph nodes, spleen,
liver and Hepa 1–6 tumor, but not in the Hepa 1–6 cell
line (Figure 2A). Therefore, the chemotactic effect of
SLC can be measured by the level of intratumoral CCR7,
and depletion of Tregs can be defined by the level of
Foxp3. We observed that the combination therapy group
and SLC group showed steady up-regulation of CCR7
on day 1 to 7 post-treatment but with the obvious
down-regulation on day 9, whereas the control group
remained the basal level of CCR7 during the same
period (Figure 2B and C). In contrast, we noticed the
combination therapy group showed the lowest level of
Foxp3 at each time point while all 3 groups exhibited a
gradually increased level of Foxp3 on day 1 to 9 post-
treatment (Figure 2B).
Altered frequency of CD4+ and CD8+ T cells at tumor sites
After quantifying infiltrating T cells in tumors, we found
the combination therapy group had the highest level of
CD8+ T cells (P < 0.01) on day 1 to 9, while the control
group showed the lowest level (P < 0.01) (Figure 3A and C).
On the contrary, the SLC group manifested the highest
level of CD4+ T cells (P < 0.05 and P < 0.01) and the
combination therapy group showed a modest increase
(P < 0.01) (Figure 3B and D) on day 1 to 9.
Cytokines profiles of IL-12, IFN-γ, IL-10 and TGF-β1 were
skewed in the TME
Compared with the control group, both treated groups
showed significantly higher levels of IL-12 (Figure 4A)
and IFN-γ (Figure 4B), but significantly lower levels of
immunosuppressive mediators IL-10 (Figure 4C) and
TGF-β1 (Figure 4D) on day 5 post-treatment, a repre-
sentative time-point for Tregs depletion and tumor
growth inhibition. However, the levels of the four cyto-
kines were not significantly different between the SLC
group and the combination therapy group.
Systemic optimization of Tregs, CD8+ and CD4+ T cells in
the lymph nodes, spleen and liver
We next evaluated the frequency of Tregs, CD8+ and
CD4+ T cells in peripheral immune organs as well as in
the liver. In lymph nodes, IHC indicated decreased
Tregs and increased CD8+ and CD4+ T cells in the two
treated groups on day 5 post-treatment (Figure 5A). FACs
Figure 1 Depletion of Tregs by anti-CD25 mAbs in SLC-treated mice. (A) Representative FACs plots of CD25+ Foxp3+ Tregs gated on CD4+
T cells in tumors on day 1 to 9 post-treatment. (B) Representative staining of Foxp3+ Tregs in the tumor tissue (dark brown). (C) A curve diagram
was summarized for the results from all treated and control mice. (D) The sharp increased frequency of Tregs from day 7 to day 9. Control: con-
trol group; SLC: SLC group; SLC + anti-CD25: combination therapy group. Values were presented as mean ± SD; n = 5 mice/group. * P < 0.05,
** P < 0.01 vs control or indicated comparison on day 1 to 9. Results were obtained in three independent experiments. Bar = 50 μm.
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groups was lower than the control group (P < 0.01) and
specifically the combination therapy group had a lower
frequency of Tregs on day 7 and 9 compared with the
SLC group (P < 0.05) (Figure 5D). The two treated groups
had higher levels of CD8+ and CD4+ T cells compared
with the control on day 3 to 9 (P < 0.01); between the two
treated groups, the combination therapy group had a
significantly higher level of CD8+ T cells on day 3 and
5, and a significantly higher level of CD4+ T cells on
day 5 (Figure 5D). The cryostat sections of the spleen
on day 5 post-treatment by IHC showed decreasedTregs and increased CD8+ and CD4+ T cells in combin-
ation therapy group and SLC group (Figure 5B). Quan-
titative results confirmed that the two treated groups
had a decreased percentage of Tregs and increased per-
centages of CD8+ and CD4+ T cells compared with the
control; furthermore, the combination therapy group
had the significantly lowest level of Tregs (day 3 to 9),
the highest level of CD8+ (day 1 to 9) and CD4+ T cells
(day 1 and 5 to 9) (Figure 5E). The two treated groups
showed a similar pattern of Tregs, CD8+ and CD4+ T cells
in the liver: decreased frequency of Tregs and increased
frequency of CD8+ and CD4+ T cells; however, the
Figure 2 Dynamic changes of CCR7 and Foxp3 in tumors after the treatments. (A) Expression of CCR7 in Hepa 1–6 cells, tumors and
immune organs. (B) Expression of CCR7 and Foxp3 in tumors on day 1 to 9 post-treatment. (C) Representative staining of CCR7 (dark brown) in
tumors on day 1 to 9 post-treatment. Control: control group; SLC: SLC group; SLC + anti-CD25: combination therapy group. β-actin was used as a
quantitative control. Densitometer quantitation was relative to the first data set in each case (indicated by a value of 1). All data are representative
of at least two independent experiments. Bar = 50 μm.
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on day 9 and the higher level of CD8+ T cells on day 3 and
9, compared with SLC group (Figure 5C and F). SLC
group had the highest level of CD4+ T cells on day 1 to
9 (P < 0.05) (Figure 5F).
The inhibition of the established HCC was stronger under
the combination therapy
The anti-tumor effects of the combination treatment were
assessed by monitoring the tumor volume and weight. We
found that the combination therapy caused maximal inhib-
ition in HCC volume (P < 0.01, day 5 to 9) (Figure 6A).
Along with the reduction of volume, the combination treat-
ment also significantly reduced tumor weight (Figure 6B).
Analyzing the invasiveness of tumors by gelatin zymogra-
phy, we found both pro- and active forms of MMP-2 and
MMP-9 were reduced in tumors treated by the combin-
ation therapy (Figure 6C) on day 5 post-treatment.
SLC induced the maturation of DCs via the NF-κB p65 in vitro
It has been demonstrated that the anti-tumor effects of
SLC can be partially attributed to the maturation of DCs
induced by SLC in tumors [6,16]; however, it is still not
clear about the detailed mechanisms underlying the
SLC-induced maturation of DCs. We analyzed the ex-
pression profiles of bone-marrow-derived dendritic cells(BMDCs) after stimulation with SLC by the genes array.
The array data showed that various genes were up-
regulated after the stimulation, such as the PKC pathway
(Ca2+, MEK, etc.), PI-3 kinase pathway and NF-κB path-
way (Table 1). We focused on the NF-κB pathway in the
present study, which was important in the maturation of
DCs. We found both SLC and ELC stimulation elicited
up-regulation of phosphorylated NF-κB p65 (p-NF-κB
p65) and down-regulation of NF-κB p65, and these
changes were blocked by PDTC, the specific inhibitor of
NF-κB activation (Figure 7A), which was consistent with
the array data. Phenotypes assessment suggested that
during this maturation BMDCs up-regulated CCR7,
CD80 and CD86, while PDTC significantly inhibited this
process (Figure 7B and C).
Discussion
In this study we demonstrated that intratumoral injection
of SLC plus anti-CD25 mAbs maximally inhibited tumor
progression in a murine HCC model. To our knowledge,
this was the first report to demonstrate the remarkable ef-
fects of SLC-based combination therapy in HCC.
We found that the frequency of Tregs remained the low-
est in the combination therapy group. This result was con-
sistent with previous studies identifying the efficacy in
depleting Tregs by anti-CD25 mAbs treatment [13,17,18].
Figure 3 Frequency of CD8+ T cells and CD4+ T cells in tumors after the treatments. Frequency of CD8+ T cells (A) and CD4+ T cells (B) in
tumors was analyzed on day 1 to 9 post-treatment by FACs gated on lymphocytes. Representative staining of CD8+ T cells (C) and CD4+ T cells
(D) in tumors (dark brown) was shown by IHC. Control: control group; SLC: SLC group; SLC + anti-CD25: combination therapy group. Values were
presented as mean ± SD; n = 5 mice/group. * P < 0.05, ** P < 0.01 vs control or indicated comparison on day 1 to 9. Results were obtained in three
independent experiments. Bar = 50 μm.
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trast to immature DCs which easily induce Tregs, we
propose the maturation of DCs induced by SLC also con-
tributed to the decreased Tregs. The intratumoral level of
Foxp3 was reversely correlated with tumor progression
[19,20] and we found the level of Foxp3 in the combination
therapy remained the lowest among the 3 groups, which
represented a beneficial anti-tumor effect.
At the same time, we found the increased level of CCR7
at tumor sites in both the SLC group and combination
therapy group, concordant with the chemotactic proper-
ties of SLC. We also noticed a sharp drop of CCR7 in SLC
group and combination therapy group from day 7 to 9. In
our opinion, this might be caused by the duration of treat-
ment and progression of the tumor in vivo, which could
be also inferred from other studies [6,17]. In support ofthis, we found the frequency of Tregs increased whereas
the CD8+ T cells and CD4+ T cells simultaneously dropped
in tumors in both the treated groups from day 7 to 9.
These observations provided useful information on the
time window for immunotherapies in HCC.
We observed that the combination therapy had the high-
est level of CD8+ T cells and modest level of CD4+ T cells.
We considered that the reduced proportion of CD4+ T cells
was due to depletion of CD4+ Tregs by anti-CD25 mAbs.
As for the increased CD8+ T cells, we reasoned two possibil-
ities: (1) Depletion of Tregs in the TME elicited a relatively
suppression-free milieu, which facilitated the proliferation of
CD8+ T cells [21,22]; (2) The residual Tregs were inactivated
and reprogramed by anti-CD25 mAbs [23-25], which sup-
ported the recruitment and survival of CD8+ T cells. This
change represented one of the anti-tumor effects.
Figure 4 Levels of the four cytokines in the tumor microenvironment. The tumor samples on day 5 post-treatment were harvested and
intratumoral levels of IL-12 (A), IFN-γ (B), IL-10 (C) and TGF-β1 (D) were evaluated by ELISA. Control: control group; SLC: SLC group; SLC + anti-
CD25: combination therapy group. Values were presented as mean ± SD; n = 5 mice/group. * P < 0.05, ** P < 0.01 for indicated comparison.
Results were obtained in three independent experiments.
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(enhancing anti-tumor immunity) and lower level of TGF-
β1 and IL-10 (suppressing anti-tumor immunity) in both
treated groups. However, the levels of the four cytokines
were not statistically significantly different between the
SLC group and the combination therapy group. As we de-
tected these cytokines on day 5, we were not sure whether
these cytokines were significantly different at the other time
points. More experiments are needed to exactly verify the
cytokines profiles in TME during the tumor progression.
Unexpectedly, we found the frequency patterns of Tregs,
CD8+ T cells and CD4+ Tcells showed similar optimization
in the lymph nodes, spleen and liver as that in TME, which
manifested decreased Tregs and increased CD8+ T cells
and CD4+ T cells. It has not been reported that SLC-based
local treatments can lead to the systemic optimization of
the immune cells in peripheral immune organs. It is not
clear how this systemic optimization occurs. We supposed
that the altered profiles of cytokines in TME, such as in-
creased the IL-12 and IFN-γ and decreased TGF-β1 and
IL-10, might exert some effects on peripheral organs. In-
deed, some studies have already confirmed that TME con-
tains many components that can affect the remoteimmune organs, e.g. the tumor-derived microvesicles and
TLR4 ligands, which induce apoptosis of T cells [26,27].
Clinical studies also have found that HCC derived soluble
factors simultaneously increased the number of Tregs and
enhanced their suppressive function [28]; removing the tu-
mors by surgery leads to systemically changed profiles of
immune cells, such as decreased Tregs and granulocytes,
and increased dendritic cells and CD4+ T cells [29,30].
The therapeutic effects of the combination therapy
were assessed by both the growth and invasiveness of tu-
mors. We found the growth of tumors was significantly
reduced in the combination therapy and SLC group
compared with the control group. Although the SLC
treatment alone decreased the growth of tumors, the
combined treatment manifested much more profound
inhibition. This result confirmed our hypothesis that the
combination therapy treatment would elicit improved ef-
ficacy, concordant with other studies combining SLC
with different adjuvants [5,31]. MMP2 and MMP9 are
important mediators for tumor progression and metasta-
sis [32], and in our experiments we observed the levels
of pro- and active-MMP2, MMP9 were the lowest in the
combination therapy group among three groups.
Figure 5 Optimization of Tregs, CD8+ and CD4+ T cells in the lymph nodes, spleen and liver. Representative staining of Foxp3+ Tregs,
CD8+ T cells and CD4+ T cells was shown by IHC in the lymph nodes (A), spleen (B) and liver (C) on day 5 post treatment (dark brown).
Quantitative analysis of Foxp3+ Tregs, CD8+ T cells and CD4+ T cells was performed by FACs in the lymph nodes (D), spleen (E) and liver
(F) on day 1 to 9 post-treatment. Control: control group; SLC: SLC group; SLC + anti-CD25: combination therapy group. Values were presented
as mean ± SD; n = 5 mice/group. * P < 0.05, ** P < 0.01 vs control or indicated comparison on day 1 to 9. Results were obtained in three
independent experiments. Bar = 50 μm.
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combination therapy.
Interestingly, we noticed that the SLC group showed
modest improvement compared with the control group
and combination therapy group as indicated by theexperiments in vivo and in vitro. These observations
were consistent with previous studies from our lab and
others which demonstrated the anti-tumor effects of
SLC [3,7]. Importantly, although we did not found stron-
ger anti-tumor effects of anti-CD25 treatment alone
Figure 6 Maximal inhibition of the established HCC under the
combination therapy. Tumor size was monitored on day 1 to 9
post-treatment (A) and mice were sacrificed and the entire tumor
was weighed (B). Gelatin zymography was used to detect intratu-
moral MMP-2 and MMP-9 activity (C). Control: control group; SLC:
SLC group; SLC + anti-CD25: combination therapy group. Values
were presented as mean ± SD; n = 5 mice/group. * P < 0.05, ** P <
0.01 vs control or indicated comparison on day 1 to 9. Results were
obtained in three independent experiments;
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periments (data not shown), in the present study we
found anti-CD25 mAbs treatment greatly boosted the
anti-tumor effects of SLC, proving the efficacy of the
combination therapy.
The DCs at the tumor sites are the key components for
anti-tumor effects and a group of studies have confirmed
the immature DCs profoundly counteract these benefits
[33,34]. Intratumoral administration of SLC has been
demonstrated to induce the maturation of DCs at tumor
sites and this maturation constitutes one of the crucial
anti-tumor effects elicited by the SLC-based treatments[6,16], which can partly explain our results. However, little
is known about the detailed mechanisms of the SLC-
CCR7 induced maturation. Our array data suggested that
SCL-CCR7 axis resulted in up-regulation of genes in NF-κB
pathway, which are important in the maturation of DCs
[35,36]. Indeed, we found SLC effectively induced the mat-
uration of BMDCs via NF-κB p65 in vitro. This finding was
highly consistent with the recently published research de-
scribing CCR2 mediated maturation of DCs through the
NF-κB pathway [37]. In addition, we also demonstrated that
SLC and ELC, the two ligands for CCR7, had the same
stimulation effects on BMDCs. These findings were very
important for answering why these two ligands for CCR7
exhibit partially overlapping expression profiles, which was
argued by Reinhold Fröster et al. [38]. Interestingly, we ob-
served more potent SLC-induced phosphorylation of NF-
κB p65 than ELC, and this might explain why SLC is the
prior ligand for CCR7 in vivo [2]. Collectively, these results
validated the new circuit underlying the maturation of DCs.
Conclusions
Taken together, our results demonstrated that the intratu-
moral administration of SLC and anti-CD25 mAbs was an
effective treatment for HCC in murine model. This combin-
ation therapy not only altered the profiles of Tregs, CD4+ T
cells and CD8+ T cells but also influenced the cytokines (IL-
12, IFN-γ, IL-10 and TGF-β1) at tumor sites. These changes
constituted an anti-tumor environment in TME. Moreover,
the combination therapy systemically optimized the profiles
of Tregs, CD4+ T cells and CD8+ T cells in peripheral im-
mune organs. The in vitro experiments confirmed that SLC
induced the maturation of DCs through NF-κB p65, which
was important for the SLC-based treatments. These results
provided an appealing strategy in immunotherapy for HCC.
Methods
Animals and cell lines
C57BL/6 J (H-2b) female mice, 6–8 weeks of age, were
purchased from the Chinese Academy of Science and
housed at the Animal Maintenance Facility of Shanghai
Medical College, Fudan University. All animal experi-
ments were performed according to the regulations of
Institutional Care of Experimental Animals Committee
of Fudan University. Hepa 1–6, the murine hepatocellular
carcinoma cell line (CRL-1830, ATCC, USA), was cultured
in DMEM (Biowest, France) with 10% heat-inactivated FBS
(GIBCO-BRL, USA), 0.1 mM nonessential amino acids,
1 μM sodium pyruvate, 2 mM L-glutamine, 100 μg/ml
streptomycin, 100 units/ml penicillin, 50 μg/ml gentamicin,
and 0.5 μg/ml fungizone.
Establishment of murine models bearing HCC
The Hepa 1–6 tumor bearing mice were established as
following: A total of 3 × 106 Hepa 1–6 cells diluted in
Table 1 Up-regulated genes in BMDCs treated with SLC for 1 or 12 hours
Unigene Genebank Description Gene name Exp.1 Exp.2 Exp.2/Exp.1
Ca2+ pathway
Mm.3064 NM_007922 M.musculus mRNA for elk1 protein Elk-1 1.509E-01 3.941E-01 2.612E + 00
Mm.195050 NM_007923 ELK4, member of ETS oncogene family Sap 1a 2.183E-02 1.673E-01 7.662E + 00
PKC pathway
Mm.896 NM_008362 Interleukin 1 receptor, type I IL-1R1 1.194E-04 9.819E-04 8.223E + 00
Protein tyrosine kinase pathway
Mm.22288 NM_007631 Cyclin D1 Cyclin D1 2.426E-02 3.758E-01 1.549E + 01
Mm.16110 NM_007633 Cyclin E1 Ccnel 4.159E-02 2.403E-01 5.778E + 00
Mm.35867 NM_009830 Cyclin E2 Cyclin E2 2.048E-01 4.335E-01 2.117E + 00
NF-κB pathway
Mm.76649 NM_011693 Vascular cell adhesion molecule 1 VCAM-1 9.880E-02 2.347E-01 2.376E + 00
JAK-STAT pathway
Mm.34446 NM_007669 Cyclin-dependent kinase inhibitor 1A (P21) p21Waf1/p21cip 8.938E-03 7.725E-02 8.642E + 00
Exp.1 represented the expression of the genes in BMDCs treated with SLC for 1 hour; Exp.2 represented the expression of genes in BMDCs treated with SLC for
12 hours; Exp.2/Exp.1 meant the fold change.
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subcutaneously into the right flank of the mice. One
week after inoculation, the mice with visible tumor were
examined for further experiments.Figure 7 NF-κB p65 mediated the maturation of DCs downstream of
with SLC or ELC for 1, 2, 4, 6, 12, 24 h. Whole cell lysates, nuclear lysates an
NF-κB p65 (A), and CCR7 (B). BMDCs were pre-treated with PDTC for 1 h a
CD86 was analyzed by FACs (C). Densitometer quantitation was relative toTreatment of established HCC in mice
On day 8 after inoculation, tumor-bearing mice were
randomly divided into 3 groups receiving different intra-
tumoral injections: (1) control group: 50 μl rat IgG1SLC. BMDCs were pre-treated with PDTC for 1 h and then cultured
d cytosol lysates were analyzed for NF-κB p65 and phosphorylated
nd then cultured with SLC for 24 h. Expression of CCR7, CD80 and
the first data set in each case (indicated by a value of 1).
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SLC group: 50 μl recombinant murine SLC (0.5 μg/dose,
PeproTech, USA); (3) combination therapy group: 50 μl
recombinant SLC (0.5 μg/dose) and rat anti mouse
CD25 monoclonal antibody (clone PC61.5, 2.5 μg/dose,
eBioScience). All the injections were administered three
times, once every other day. Tumor size and weight was
monitored every other day for 9 days after the last injec-
tion. Tumor volume was calculated by the formula:
V (in mm3) = 0.4(ab2), where a was the long diameter
and b was the short diameter.IHC analysis
Tumor samples were embedded in OCT compound
(Sakura, Japan) before being snap frozen in liquid nitro-
gen and stored at − 76°C until immunohistochemical
procedures were performed. Serial 5-μm-thick cryostat
sections were prepared and stained with antibodies
against Foxp3, CCR7, CD4, CD8 (eBioScience).Western blot
Tumor tissues on day 1 to 9 post-treatment were homoge-
nized with RIPA lysis buffer (Beyotime, China) and equal
amounts of denatured proteins were used for immunoblot-
ting with antibodies against CCR7, Foxp3 (eBioScience).
BMDCs were pretreated with PDTC (100 μM, Sigma), the
specific inhibitor of NF-κB activation, for 1 h and then stim-
ulated with SLC (200 ng/ml) or ELC (200 ng/ml, Pepro-
Tech) for 1, 2, 4, 6, 12, 24 h. Cell lysates were
immunoblotted with antibodies against CCR7, NF-κB p65,
phosphorylated NF-κB p65, β-actin (Cell Signaling Technol-
ogy) and Lamin B1 (Santa Cruz, USA). Band intensities
were quantified using Band Leader software (Magnitec,
Israel).Flow cytometry
Tumors, lymph nodes, spleens and livers were mechanically
dissociated to produce a single cell suspension. Cells were
then stained with antibodies against CD4, CD25, Foxp3,
CD8 (eBioScience). BMDCs stimulated with SLC in the
presence or absence of PDTC were stained with CCR7,
CD80 and CD86 (eBioscience). Isotype-matched antibodies
were used as controls. All the samples were acquired on a
FACSCalibur (Becton Dickinson, USA) and analyzed with
WinMDI 2.9 (USA).ELISA for cytokines
Tumor tissues were collected and homogenized on day
5 post-treatment and supernatants were used for evalu-
ating cytokines (IL-12, IFN-γ, IL-10, and TGF-β1) using
commercially available ELISA kits (eBioScience). Data
was expressed at pg/mg tumor tissue.Gelatin zymography
Tumor tissues were homogenized on day 5 post-
treatment and loaded onto zymographic sodium dodecyl
sulfate gel containing gelatin (1 mg/ml, Sigma, Germany).
Then the gels were incubated for 24 h at 37°C. The en-
zyme activity was visualized by staining the gel with
Coomassie Blue R-250.
Generation of BMDCs and SLC/ELC stimulation
Mouse BMDCs (bone-marrow-derived dendritic cells)
were generated as previous described [3]. In brief, bone
marrow cells were cultured in RPMI 1640 containing
10% FBS with GM-CSF, IL-4 and tumor necrosis factor-
α (TNF-α). Non-adherent cells were harvested and
sorted by anti-CD11c microbeads (Miltenyi, Germany).
Analysis by flow cytometry revealed that the purity of
the BMDCs was consistently more than 90%, and the
phenotype was characterized as MHC IIhigh CD86low. Al-
iquots of 2 × 106 cells were incubated in RPMI 1640 with
10% FBS and HEPES buffer for 30 min, and were then
stimulated with SLC or ELC.
G protein-coupled receptors signaling PathwayFinder
gene array
Total RNAs were purified from BMDCs stimulated with
SLC for 1 or 12 hours by Trizol reagent (Invitrogen, USA).
RNAs were arrayed by the G Protein-coupled Receptors Sig-
naling PathwayFinder Gene Array (SuperArray Bioscience
Corporation, USA). Differentially expressed genes were
identified according to GeneChip® Expression Analysis-Data
Analysis Fundamentals. The arrays were repeated 3 times.
Data-mining tools used in this study included PubMatrix
(http://pubmatrix.grc.nia.nih.gov), Gene Map Annotator and
Pathway Profiler 2.0 (http://www.GenMapp.org).
Statistical analysis
For comparisons of the various treatment groups, ANOVA
was performed with the Bonferroni correction. All stat-
istical analyses were performed using the SPSS statis-
tical software package (SPSS 20.0 for Windows, USA).
Differences were considered statistically significant with
* P < 0.05 and highly significant with ** P < 0.01.
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